Aeglea BioTherapeutics posts corporate presentation showing anti-TL1A antibody SPY002 with picomolar potency

Spyre Therapeutics, Inc.

Non-clinical data for SPY002 (anti-TL1A antibody) show monomer and trimer binding at picomolar potencies.
Corporate presentation posted on October 24, 2023, includes updates on research pipeline.
No new financial results, guidance, or material operational changes disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.